Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App helps manage side effects of kidney cancer combo therapy

NCT ID NCT07028125

Disease control Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tests whether a digital app that tracks symptoms weekly can help doctors better manage side effects in people with advanced kidney cancer taking cabozantinib and nivolumab. About 83 patients will use the app to report how they feel, and doctors can adjust treatment based on the reports. The goal is to see if this approach reduces unplanned hospital visits or treatment changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cabozantinib and nivolumab
What this could lead to
If successful, this could show that digital monitoring helps doctors adjust treatment more quickly, improving quality of life for kidney cancer patients.
What could go wrong
This is a small, early-phase study (83 people) focused on monitoring, not on curing the cancer. The digital tool may not lead to better outcomes or may be burdensome for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 83 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient older than 18 years * Diagnosis of advanced/metastatic Renal Cell Carcinoma (RCC) with a clear-cell component * No prior systemic treatment for RCC * Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, in first line for advanced/metastatic RCC, according to approved local labels * Female subjects of childbearing potential must not be pregnant at screening and during treatment by Cabozantinib and Nivolumab. Effective methods of contraception must be used throughout the course of treatment and for at least 5 months after the end of treatment. Sexually active fertile subjects and their partners must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the study and 5 months after the last dose of study treatment, even if oral contraceptives are also used. * Subject affiliated to an appropriate social security system * Patient has signed informed consents obtained before any trial related activities and according to local guidelines Exclusion Criteria: * Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol * Current participation in another clinical study and/or in an investigational program with any intervention that could possibly interfere with the treatment and impact this study * Patient with history of allergy or hypersensitivity to components of the study drugs * Patient with contraindication to the study drugs * Pregnant or lactating woman * Patient unable to use digital tools * Patient deprived of liberty or placed under the authority of a tutor * Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced clear cell renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma kidney cancer Neoplasm Metastasis renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced Metastatic renal cell carcinoma Renal cell carcinoma (kidney cancer)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Boulogne sur Mer

    NOT_YET_RECRUITING

    Boulogne-sur-Mer, France

  • CHU

    NOT_YET_RECRUITING

    Saint-Etienne, France

  • Centre Antoine Lacassagne

    NOT_YET_RECRUITING

    Nice, France

  • Centre François Baclesse

    RECRUITING

    Caen, France

  • Centre Hospitalier d'Annecy

    NOT_YET_RECRUITING

    Annecy, France

  • Centre Hospitalier de Bayeux

    NOT_YET_RECRUITING

    Bayeux, France

  • Centre Hospitalier de Lorient

    NOT_YET_RECRUITING

    Lorient, France

  • Centre Hospitalier de Tours

    NOT_YET_RECRUITING

    Tours, France

  • Centre Léon Bérard

    NOT_YET_RECRUITING

    Lyon, France

  • Centre d'oncologie St Yves

    NOT_YET_RECRUITING

    Vannes, France

  • Chu Montpellier

    NOT_YET_RECRUITING

    Montpellier, France

  • Chu Poitiers

    NOT_YET_RECRUITING

    Poitiers, France

  • GHR Mulhouse Sud Alsace

    RECRUITING

    Mulhouse, France

  • Ghpso Creil

    NOT_YET_RECRUITING

    Creil, France

  • Hôpital FOCH

    NOT_YET_RECRUITING

    Suresnes, France

  • Institut Andrée Dutreix

    NOT_YET_RECRUITING

    Coudekerque-Branche, France

  • Institut Sainte Catherine

    RECRUITING

    Avignon, France

  • Institut de cancérologie de Bourgogne

    NOT_YET_RECRUITING

    Dijon, France

  • Polyclinique du Parc Elsan

    NOT_YET_RECRUITING

    Caen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.